2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
1262
Specimen Handling
924
Magnetic Resonance Spectroscopy
829
Carboplatin
821
Cyclophosphamide
799
Cisplatin
722
Nivolumab
667
Paclitaxel
627
Radiotherapy
608
Gemcitabine
570
Biopsy
557
Bevacizumab
478
Dexamethasone
437
fludarabine
407
Docetaxel
377
venetoclax
367
Oxaliplatin
364
Capecitabine
355
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
329
Drug Therapy
325
Doxorubicin
316
Radiosurgery
314
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
304
Ipilimumab
298
Radiation
285
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Serotonin 5-HT3 Receptor Antagonists
×
1 year
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled